BRPI0514725A - efeito neuroprotetor de udca solubilizado no modelo isquêmico focal - Google Patents

efeito neuroprotetor de udca solubilizado no modelo isquêmico focal

Info

Publication number
BRPI0514725A
BRPI0514725A BRPI0514725-5A BRPI0514725A BRPI0514725A BR PI0514725 A BRPI0514725 A BR PI0514725A BR PI0514725 A BRPI0514725 A BR PI0514725A BR PI0514725 A BRPI0514725 A BR PI0514725A
Authority
BR
Brazil
Prior art keywords
udca
neuroprotective effect
values
days post
ischemic model
Prior art date
Application number
BRPI0514725-5A
Other languages
English (en)
Inventor
Seo Hong Yoo
Original Assignee
Seo Hong Yoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seo Hong Yoo filed Critical Seo Hong Yoo
Publication of BRPI0514725A publication Critical patent/BRPI0514725A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/723—Xanthans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EFEITO NEUROPROTETOR DE UDCA SOLUBILIZADO NO MODELO ISQUêMICO FOCAL A presente divulgação fornece composições e métodos para o tratamento, melhora, ou alívio de pelo menos um sintoma associado à perda do fluxo sangüíneo no cérebro, incluindo, sem limitação, derrame isquêmico. As composições dá divulgação podem compreender um composto de ácido biliar e um carboidrato, onde ambos materiais permanecem em solução para todos os valores de pH em uma escala selecionada de valores de pH. Os sintomas podem incluir volume de infarto, recuperação funcional, apoptose, e/ou expressão de eNOS. Controle (2 dias pós-isquêmico) 100 mg de UDCA (2 dias pós-isquêmico).
BRPI0514725-5A 2004-08-30 2005-08-30 efeito neuroprotetor de udca solubilizado no modelo isquêmico focal BRPI0514725A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60556604P 2004-08-30 2004-08-30
US62999804P 2004-11-22 2004-11-22
PCT/US2005/030679 WO2006026555A2 (en) 2004-08-30 2005-08-30 Neuroprotective effect of solubilized udca in focal ischemic model

Publications (1)

Publication Number Publication Date
BRPI0514725A true BRPI0514725A (pt) 2008-06-24

Family

ID=35702324

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514725-5A BRPI0514725A (pt) 2004-08-30 2005-08-30 efeito neuroprotetor de udca solubilizado no modelo isquêmico focal

Country Status (14)

Country Link
US (1) US8173627B2 (pt)
EP (1) EP1789057B1 (pt)
JP (1) JP2008511651A (pt)
KR (1) KR101414810B1 (pt)
CN (1) CN101035541B (pt)
AT (1) ATE458489T1 (pt)
AU (1) AU2005279961B2 (pt)
BR (1) BRPI0514725A (pt)
CA (1) CA2577268A1 (pt)
DE (1) DE602005019582D1 (pt)
ES (1) ES2339790T3 (pt)
IL (1) IL181434A (pt)
RU (1) RU2428987C2 (pt)
WO (1) WO2006026555A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7145125B2 (en) * 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US8173627B2 (en) 2004-08-30 2012-05-08 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
US9629838B2 (en) * 2004-09-16 2017-04-25 Morehouse School Of Medicine Composition for reducing nervous system injury and method of making and use thereof
EP1809330B1 (en) 2004-10-15 2011-04-27 Seo Hong Yoo Compositions for reducing toxicity of cisplatin, carboplatin, and oxaliplatin
KR101358078B1 (ko) * 2004-11-01 2014-02-06 주식회사 유스팜인터내셔널 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2694063A1 (en) * 2011-04-01 2014-02-12 The Medicines Company Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage
PT2770988T (pt) 2011-10-24 2016-09-05 Som Innovation Biotech S L Nova terapêutica para a amiloidose associada à transtirretina
WO2014066318A1 (en) 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US10603316B2 (en) 2013-08-21 2020-03-31 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks
CN110742891B (zh) 2013-08-21 2024-04-05 莫尔豪斯医学院 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
KR101555945B1 (ko) 2014-11-27 2015-09-25 부산대학교 산학협력단 Ｔｕｄｃａ를 이용한 줄기세포 생물작용 활성 증가, 및 이를 포함하는 줄기세포 치료 보조제
KR20180081812A (ko) * 2015-11-23 2018-07-17 아즈테라피즈 인코포레이티드 허혈성 뇌졸중 치료용 조성물 및 방법
CN105853473B (zh) * 2016-03-31 2019-12-13 海南合瑞制药股份有限公司 一种奥拉西坦的药物组合物及其制备方法
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
KR20180036580A (ko) 2016-09-30 2018-04-09 주식회사 유스바이오팜 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
WO2018080276A1 (ko) * 2016-10-31 2018-05-03 사회복지법인 삼성생명공익재단 담즙산을 포함하는 허혈성 재관류 손상의 예방 또는 치료용 약학적 조성물
KR102252450B1 (ko) * 2017-02-09 2021-05-14 주식회사 아미코젠파마 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
WO2018147685A1 (ko) * 2017-02-09 2018-08-16 주식회사 유스바이오팜 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
CA3070386A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
JP2018138592A (ja) * 2018-05-08 2018-09-06 モアハウス スクール オブ メディスンＭｏｒｅｈｏｕｓｅ Ｓｃｈｏｏｌ Ｏｆ Ｍｅｄｉｃｉｎｅ 神経系損傷を減少させるための組成物及びその製造方法及び使用
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
US10980757B2 (en) 2018-09-06 2021-04-20 RTU Pharma SA Ready-to-use tranexamic acid intravenous solution
CN109288850B (zh) * 2018-11-21 2019-10-29 浙江大学 熊脱氧胆酸或其药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
JP2020079289A (ja) * 2020-02-07 2020-05-28 モアハウス スクール オブ メディスンＭｏｒｅｈｏｕｓｅ Ｓｃｈｏｏｌ Ｏｆ Ｍｅｄｉｃｉｎｅ 神経系損傷を減少させるための組成物及びその製造方法及び使用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4036954A (en) 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4092428A (en) 1973-11-02 1978-05-30 Yamanouchi Pharmaceutical Co., Ltd. Process of preparing stable prostaglandin E group-containing formulation
US4113882A (en) 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
JPS5522616A (en) 1978-08-04 1980-02-18 Tokyo Tanabe Co Ltd Bile acid inclusion compound and injection containing the same
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
FR2521430A1 (fr) 1982-02-12 1983-08-19 Pan Medica Solution aqueuse d'acide ursodesoxycholique a usages therapeutiques, son procede de preparation et application au traitement des lithiases biliaires
GB8313217D0 (en) 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
GB8417895D0 (en) 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition
JPS61171421A (ja) 1985-08-23 1986-08-02 Yamanouchi Pharmaceut Co Ltd 安定なプロスタグランジンｅ類製剤の製造方法
JPS62153220A (ja) 1985-12-27 1987-07-08 Tokyo Tanabe Co Ltd 胆汁酸内用水剤
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
JPH0747539B2 (ja) 1986-10-22 1995-05-24 東京田辺製薬株式会社 胆汁酸固形製剤
JPS63243031A (ja) 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
HU203204B (en) 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
NZ226557A (en) 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5446026A (en) 1989-08-09 1995-08-29 Advanced Peptides & Biotechnology Sciences Potent non-opiate analgesic
US5157022A (en) 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
WO1991015548A1 (en) 1990-04-04 1991-10-17 Berwind Pharmaceutical Services, Inc. Aqueous maltodextrin and cellulosic polymer film coatings
US5057321A (en) 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1245889B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
IT1245890B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
IT1245891B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
CH680704A5 (pt) 1991-05-15 1992-10-30 Medichemie Ag
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
HU209251B (en) 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
US5292534A (en) 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5342934A (en) 1992-06-19 1994-08-30 The Trustees Of Columbia University In The City Of New York Enantioselective receptor for amino acid derivatives, and other compounds
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
IT1255968B (it) 1992-11-27 1995-11-17 Composizioni farmaceutiche contenenti acido ursodesossicolico
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
CA2159219A1 (en) 1993-03-31 1994-10-13 Minoru Maeda Cholestasis ameliorant
LU88375A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Produit énergétique stimulant la puissance virile
EP0773029A4 (en) 1993-07-19 1997-09-03 Tokyo Tanabe Co HEPATITIS C VIRUS PROLIFERATION INHIBITOR
DE59407041D1 (de) 1993-08-30 1998-11-12 Medichemie Ag Ursodeoxycholsäure enthaltendes Arzneimittel in flüssiger Darreichungsform
GB9405833D0 (en) 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
DE4432708A1 (de) 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5686588A (en) 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
WO1997034608A1 (en) 1996-03-22 1997-09-25 Mayo Foundation For Medical Education And Research Combinations of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US20010011146A1 (en) 1997-04-23 2001-08-02 Tong H. Joh Neuroprotective compounds and uses thereof
DE29717252U1 (de) 1997-09-26 1998-02-19 Falk Pharma Gmbh Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
WO1999061481A1 (en) 1998-05-28 1999-12-02 Mediplex Corporation, Korea Amphiphilic polysaccharide derivatives
KR100314496B1 (ko) 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
US6407117B1 (en) 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
EP1091741A4 (en) 1998-06-30 2002-12-18 Lilly Co Eli AZEPINE DERIVATIVES PLAYING A ROLE IN SEROTONIN ASSOCIATED SYSTEMS
US20070072828A1 (en) 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
BR9912395A (pt) * 1998-07-24 2001-10-16 Seo Hong Yoo Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001000809A1 (en) 1999-06-30 2001-01-04 University Of Utah Research Foundation Self-induced deletion of dna
EP2845596A3 (en) * 2000-01-10 2015-07-15 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
WO2001056547A2 (en) 2000-02-04 2001-08-09 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2002005660A2 (en) 2000-07-18 2002-01-24 The Nutrasweet Company Drying of neotame with co-agents
US20030044413A1 (en) 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
AU2002351986A1 (en) 2002-06-19 2004-01-06 Braun Gmbh Method and device for producing injection-molded parts during an injection molding method, particularly toothbrushes or toothbrush bodies
AU2003261424A1 (en) 2002-08-06 2004-02-23 Nitromed, Inc. Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
ATE451108T1 (de) 2002-11-07 2009-12-15 Univ Minnesota Verfahren zur behandlung von verletzungen des nervensystems in verbindung mit einer blutung
JP2006514097A (ja) 2003-04-02 2006-04-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 細胞生育促進方法
US8173627B2 (en) 2004-08-30 2012-05-08 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
EP1809330B1 (en) 2004-10-15 2011-04-27 Seo Hong Yoo Compositions for reducing toxicity of cisplatin, carboplatin, and oxaliplatin
KR101358078B1 (ko) 2004-11-01 2014-02-06 주식회사 유스팜인터내셔널 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물
CA2588168A1 (en) 2004-11-24 2006-06-01 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7308768B2 (en) * 2005-02-04 2007-12-18 Target Brands, Inc. Lenticular sign

Also Published As

Publication number Publication date
WO2006026555A3 (en) 2006-07-13
EP1789057A2 (en) 2007-05-30
KR20070053238A (ko) 2007-05-23
AU2005279961A1 (en) 2006-03-09
ATE458489T1 (de) 2010-03-15
US20060051319A1 (en) 2006-03-09
WO2006026555A2 (en) 2006-03-09
IL181434A0 (en) 2007-07-04
DE602005019582D1 (de) 2010-04-08
ES2339790T3 (es) 2010-05-25
RU2007106563A (ru) 2008-10-10
AU2005279961B2 (en) 2010-05-13
RU2428987C2 (ru) 2011-09-20
CN101035541B (zh) 2012-05-30
CN101035541A (zh) 2007-09-12
KR101414810B1 (ko) 2014-07-18
CA2577268A1 (en) 2006-03-09
EP1789057B1 (en) 2010-02-24
IL181434A (en) 2012-05-31
US8173627B2 (en) 2012-05-08
JP2008511651A (ja) 2008-04-17

Similar Documents

Publication Publication Date Title
BRPI0514725A (pt) efeito neuroprotetor de udca solubilizado no modelo isquêmico focal
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
EA201000321A1 (ru) Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола
ECSP088139A (es) Métodos para prevenir y tratar trastornos metabólicos y nuevos derivados de pirazol-o-glucósido
NO20053041L (no) Behandling av diabetes.
BRPI0415397A (pt) métodos e reagentes para o tratamento de desordens imunoinflamatórias
BRPI0519181A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, e, mÉtodos para produzir um efeito inibitàrio de b-raf em um animal de sangue quente, para produzir um efeito anti-cÂncer em um animal de sangue quente e para tratar uma doenÇa em um animal de sangue quente
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
EA201000515A1 (ru) Активаторы глюкокиназы
BR0312851A (pt) Composto, composição farmacêutica, e, métodos para tratar ou previnir câncer, degeneração macular de tipo úmido ou artrite reumatóide, vascularização anÈmala, nìveis de cobre em excesso em um paciente, obesidade e doença neurodegenerativa em um paciente
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
BRPI0721062A2 (pt) métodos para prevenir ou retardar o início e para prevenir a progressão de diabete autoimune latente, métodos para tratamento de diabete autoimune latente em adultos e para tratar ou prevenir diabete de tipo 1 de início na idade adulta ou para melhorar seus sintomas em um paciente sofrendo do mesmo, e, método para prevenir ou retardar requisição de insulina em um paciente.
TW200740452A (en) Therapeutic gastrodia extracts
BRPI0415249A (pt) terapia de combinação para infecção por hcv
BRPI0408744A (pt) 4-feniltetrahidroisoquinolinas substituìdas, processos para preparação das mesmas, seu uso como medicamento, bem como medicamento que contém as mesmas
ATE444744T1 (de) Komplementäre zusammensetzungen zur verringerung der blutzuckerspiegel und zur behandlung von diabetes
Omonkhua et al. Long term anti-diabetic, anti-hyperlipidaemic and anti-atherogenic effects of Carica papaya leaves in streptozotocin diabetic rats.
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
US9308223B2 (en) Om vitamin formula
Kulasekararaj et al. BCX9930, a potent, selective, oral factor D inhibitor, demonstrates proof-of-concept as monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)
Sokolow et al. Cedilanid, with special reference to its intravenous use
BRPI0407199A (pt) (benzoimidazol-2-il)-fenil-aminas n-substituìdas, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como o medicamento contendo as mesmas
Patil Ayurvedic management of Vatarakta with special reference to Gout: A Case Study

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2269 DE 01/07/2014.